Document is current
Any future updates will be listed below
-
Authors
Gramlich, Michael
Pane, Luna Simona
Zhou, Qifeng
Chen, Zhifen
Murgia, Marta
Schötterl, Sonja
Goedel, Alexander
Metzger, Katja
Brade, Thomas
Parrotta, Elvira
Schaller, Martin
Gerull, Brenda
Thierfelder, Ludwig
Aartsma‐Rus, Annemieke
Labeit, Siegfried
Atherton, John J
McGaughran, Julie
Harvey, Richard P
Sinnecker, Daniel
Mann, Matthias
Laugwitz, Karl‐Ludwig
Gawaz, Meinrad Paul
Moretti, Alessandra
-
Funding
Funding for this research was provided by:
German Foundation for Heart Research (F/51/10)
German Research Foundation (GR3411/2‐1)
German Research Foundation (Transregio‐SFB 19)
German Research Foundation (KFO274)
German Research Foundation (Mo 2217/1‐1)
German Research Foundation (La 1238 3‐1/4‐1)
German Research Foundation (Si 1747/1‐1)
European Research Council (ERC 261053)
DZHK
National Health and Medical Research Council of Australia (573703)
National Health and Medical Research Council of Australia (573705)
- License Information
-
More Information
Article History
Received: 16 January 2015
Revised: 12 February 2015
Accepted: 17 February 2015
First Online: 10 March 2015
Conflict of interest
: AA‐R reports being employed by LUMC, which has patent applications on exon skipping for Duchenne muscular dystrophy that have been exclusively licensed to Prosensa. As coinventor on some of these patents, AA‐R is entitled to a share or royalties. The remaining authors declare that they have no conflict of interest.
